Advertisement
Advertisement
Mesoblast Sees 69% Revenue Surge for Ryoncil® Amid Expanding Market Reach
PremiumCompany AnnouncementsMesoblast Sees 69% Revenue Surge for Ryoncil® Amid Expanding Market Reach
26d ago
JPMorgan Chase & Co. Ceases Substantial Holding in Mesoblast Limited
Premium
Company Announcements
JPMorgan Chase & Co. Ceases Substantial Holding in Mesoblast Limited
1M ago
Mesoblast Limited Announces Cessation of Securities
Premium
Company Announcements
Mesoblast Limited Announces Cessation of Securities
1M ago
Mesoblast’s Ryoncil® Gains Medicare & Medicaid J-Code for Enhanced Access
PremiumCompany AnnouncementsMesoblast’s Ryoncil® Gains Medicare & Medicaid J-Code for Enhanced Access
1M ago
Mesoblast’s U.S. Origin Cell Therapies Exempt from Tariffs
Premium
Company Announcements
Mesoblast’s U.S. Origin Cell Therapies Exempt from Tariffs
2M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
2M ago
Buy Rating for Mesoblast Driven by Strong Ryoncil Launch and Strategic Financial Moves
PremiumRatingsBuy Rating for Mesoblast Driven by Strong Ryoncil Launch and Strategic Financial Moves
2M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
2M ago
Mesoblast Limited Announces New Securities Placement
Premium
Company Announcements
Mesoblast Limited Announces New Securities Placement
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100